TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12856481
Drug: Reduced digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced digoxin synthesis with downregulated tryptophan catabolism (decreased serotonin, strychnine, nicotine) and upregulated tyrosine catabolism (increased dopamine, noradrenaline, morphine) in normal sleep patterns with left hemispheric dominance
Study: 26943843
Drug: Transfusion threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion threshold of 10 g/dl
Study: 26943843
Drug: Transfusion threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion threshold of 7 g/dl
Study: 24942833
Drug: Higher NT-proBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher NT-proBNP (≥450ng/l)
Study: 22401633
Drug: Immunoxel (Dzherelo)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunoxel (Dzherelo) administered once-daily along with TB drugs
Study: 20590480
Drug: Bacopa monnieri
Normalized name: BACOPA MONNIERI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacopa monnieri (BacoMind(TM)) 300 mg/day
Study: 15819764
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intrathecal morphine
Study: 1911676
Drug: 4.0 ml
Normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 ml of 2% lignocaine containing 1:80000 adrenaline
Study: 1911676
Drug: 4.0 ml
Normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 ml of 2% lignocaine (adrenaline-free)
Study: 24380765
Drug: Daily Undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Undulating Periodized (DUP) training
Study: 22324488
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg, once daily for 3 days)
Study: 100818
Drug: Intravenous methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylphenidate (0.5 mg/kg)
Study: 15893916
Drug: Daily chlorpromazine-equivalent
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily chlorpromazine-equivalent dose of antipsychotics
Study: 9583339
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment (DT)
Study: 9583339
Drug: Nondiet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondiet treatment (NDT)
Study: 9583339
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment (DT) and Nondiet treatment (NDT)
Study: 6240831
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol HCl + 25 mg chlorthalidone
Study: 6240831
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg atenolol + 25 mg chlorthalidone
Study: 25278405
Drug: 24-hour reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour reports filled out by nurses daily
Study: 15881487
Drug: lumiracoxib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 50 mg, 100 mg, 200 mg bid, 400 mg od
Study: 15881487
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg bid
Study: 15881487
Drug: lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 100 mg bid, 200 mg bid, 400 mg od
Study: 15881487
Drug: lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 100 mg, 400 mg
Study: 15881487
Drug: lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 400 mg
Study: 15881487
Drug: ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 400 mg
Study: 11870017
Drug: D-cycloserine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine, 50 mg/day
Study: 8509235
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg/2 ml vials, 3 vials a day for 3 days)
Study: 8509235
Drug: Nisidin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisidin (2 ml vials, 3 vials a day for 3 days)
Study: 2949588
Drug: PN 200‐110
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN 200‐110 (isradipine) 15 mg
Study: 19954773
Drug: Cost treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost treatment condition
Study: 19954773
Drug: Probability treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probability treatment condition
Study: 15694232
Drug: haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 15 mg/day plus allopurinol 300 mg/day
Study: 14499318
Drug: haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 15 mg/day plus placebo
Study: 27138798
Drug: Escitalopram, Sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, Sertraline, or Venlafaxine (8 weeks treatment, dosage adjusted by clinician)
Study: 27138798
Drug: Sertraline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (8 weeks treatment, dosage adjusted by clinician)
Study: 22541248
Drug: pitrakinra (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: pitrakinra (1, 3, or 10 mg twice daily)
Study: 19850637
Drug: sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400 mg b.i.d.)
Study: 18630549
Drug: Integrated Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Chinese and western medicine group
Study: 18630549
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) group
Study: 12238266
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg cis-atracurium (group C)
Study: 2140251
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 75 mg dipyridamole with 330 mg acetylsalicylic acid (ASA) tid (high dose)
Study: 2140251
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 75 mg dipyridamole with 100 mg acetylsalicylic acid (ASA) tid (low dose)
Study: 66425
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (metiamide and cimetidine)
Study: 66425
Drug: Control (antacids)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (antacids)
Study: 28298396
Drug: Dairy group
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy group (low-fat milk or yogurt servings providing ≥1200 mg Ca/d)
Study: 28298396
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual diet of ≤600 mg Ca/d)
Study: 25577134
Drug: XELOXIRI/bevacizumab regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOXIRI/bevacizumab regimen (oxaliplatin 100 mg/m², capecitabine 1,700 mg/m²/day, irinotecan 150 mg/m², bevacizumab 7.5 mg/kg)
Study: 19949772
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg/week for 3 months
Study: 19949772
Drug: Combined therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy: Alendronate 70 mg/week, vitamin D 2800 IU/week, and calcium 1 g/day for 12 months
Study: 19949772
Drug: Calcium 1
Normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1 g/day and vitamin D 800 IU/day
Study: 8905958
Drug: Gas barrier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas barrier type tube (group G, n = 11)
Study: 6604680
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplements (500 mg/day i.m. for 1 month)
Study: 25276736
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera and Calendula Ointment every 8 hours for 5 days
Study: 18219235
Drug: Modafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (up to 400 mg)
Study: 8857856
Drug: High-dose adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adenosine cardioplegia
Study: 2000739
Drug: Thrombolytic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic and antithrombotic treatment (streptokinase initiated late, heparin infusion for at least 5 days, warfarin and dipyridamole for at least 3 months)
Study: 6391075
Drug: Naproxen (prostaglandin-inhibitor)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (prostaglandin-inhibitor)
Study: 12067837
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion alone
Study: 22236501
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) - omeprazole; n:19
Study: 22236501
Drug: Histamine H(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H(2) -receptor antagonists (H(2) RAs) - ranitidine; n:16
Study: 22236501
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) - omeprazole; n:11 (previously H(2) RA nonresponders)
Study: 22236501
Drug: Histamine H(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H(2) -receptor antagonists (H(2) RAs) - ranitidine; n:1 (previously H(2) RA nonresponder)
Study: 21199406
Drug: Active agent
Normalized name: Capillary active agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active agent
Study: 18053382
Drug: Self-administered medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered medication (SAM)
Study: 18053382
Drug: Standard administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard administration by nurses
Study: 14680716
Drug: Alprazolam and
Normalized name: Alprazolam and propranolol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam and imipramine (placebo-controlled drug trial)
Study: 10386282
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of droperidol 1.25 mg
Study: 10386282
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of droperidol 1.25 mg
Study: 10386282
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of droperidol 1.25 mg and ondansetron 4 mg in combination
Study: 10386282
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of droperidol 1.25 mg and ondansetron 4 mg in combination
Study: 2011945
Drug: Oral cyclosporin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin‐A (CyA) at 7.5 mg/kg
Study: 2011945
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (decreasing doses from 0.8 mg/kg)
Study: 6123079
Drug: At-home family
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home family therapy
Study: 23063389
Drug: Intraosseous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous anesthesia using Quicksleeper (IO injection)
Study: 15826314
Drug: Beclomethasone Dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate (QVAR) 100 mcg 2 puffs 2 times a day for 6 weeks
Study: 9797484
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (750 mg/day calcium and 400 IU/day vitamin D)
Study: 11397884
Drug: Raloxifene (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (both doses)
Study: 2715372
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of cefotetan (1 g)
Study: 2715372
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of cefotetan (1 g)
Study: 318916
Drug: Intravenous loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous loading course of 5-fluorouracil
Study: 318916
Drug: Weekly intravenous
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intravenous schedule of 5-fluorouracil
Study: 318916
Drug: Oral schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral schedule of 5-fluorouracil
Study: 30431171
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser combined with topical TXA
Study: 30431171
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser combined with intradermal TXA
Study: 25892016
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with 1.25 mg intravitreal bevacizumab every 12 weeks after loading doses
Study: 25892016
Drug: As-needed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed treatment with 1.25 mg intravitreal bevacizumab every 12 weeks after loading doses
Study: 24098469
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 5 g/d for 5 days followed by 5 g/d)
Study: 24098469
Drug: Placebo (dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrose at the same dosage)
Study: 22016254
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEEs; 0.625 mg/day)
Study: 20034232
Drug: N-acetylcysteine (NAC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC, 1.8 g/day, 3 days)
Study: 20034232
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid (ALA, 1.2 g/day, 3 days)
Study: 20034232
Drug: taurine (TAU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: taurine (TAU, 3 g/day, 3 days)
Study: 9358198
Drug: Meropenem administered
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem administered by injection over 2 minutes
Study: 9358198
Drug: Meropenem administered
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem administered by injection over 3 minutes
Study: 9358198
Drug: Meropenem administered
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem administered by injection over 5 minutes
Study: 8205299
Drug: Spirapril 6
Normalized name: spirapril 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 6 mg with isradipine 5 mg
Study: 28002359
Drug: MenACWY‐TT coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐TT coadministered with routine childhood vaccines
Study: 28002359
Drug: MenACWY‐TT coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐TT coadministered with childhood vaccines
Study: 25815491
Drug: Regular inhalation
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhalation of salmeterol/fluticasone propionate (SM/FP)
Study: 25815491
Drug: Intermittent inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent inhalation of salmeterol/fluticasone propionate (SM/FP)
Study: 23490288
Drug: LOS +
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LOS + HCTZ (losartan 50 mg/d + hydrochlorothiazide 12.5 mg/d)
Study: 23490288
Drug: LOS +
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LOS + CCB (losartan 50 mg/d + amlodipine 5 mg/d)
Study: 17698328
Drug: Atomoxetine (max.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (max. 1.8 mg/kg/d)
Study: 15309547
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg) and alpha-tocopherol (1,200 IU) daily for 37 days
Study: 11145854
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma therapy
Study: 11145854
Drug: Thymopentin therapy
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin therapy
Study: 9302748
Drug: Bivalent live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent live attenuated influenza A vaccine (10^6 TCID50)
Study: 10960435
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (endoscopic variceal ligation, nadolol, and sucralfate)
Study: 8822220
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with hyperoxic gas mixtures at fixed frequency and tidal volume (twice resting ventilation)
Study: 27114197
Drug: Tadalafil once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil once-daily (OAD)
Study: 27114197
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg (low dose) PRN
Study: 27114197
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg (high dose) PRN
Study: 27114197
Drug: Tadalafil 2.5
Normalized name: tadalafil 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 2.5 mg (low dose) OAD
Study: 27114197
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg (high dose) OAD
Study: 22569995
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (500 mg aspirin and 300 mg clopidogrel before intervention, followed by 100 mg aspirin and 75 mg clopidogrel daily for 6 months)
Study: 22569995
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (500 mg aspirin before intervention, followed by placebo instead of clopidogrel)
Study: 15914526
Drug: Nandrolone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone (150 mg IM biweekly)
Study: 20974577
Drug: Testosterone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (250 mg IM biweekly)
Study: 8758241
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PSA (> 10 micrograms/l) and DRE
Study: 24468257
Drug: rhC1INH (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhC1INH (50 IU/kg to maximum 4,200 IU/treatment)
Study: 22834291
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with remaxol (800 ml/day)
Study: 22834291
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with sterofundine-G-5
Study: 22834291
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with ringer's lactate and 10% glucose solution (1:1)
Study: 22834291
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with remaxol
Study: 1378382
Drug: Methohexital 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital 0.7 mg/kg
Study: 1378382
Drug: Methohexital 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital 1.5 mg/kg
Study: 6543314
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 80 mg single dose
Study: 6543314
Drug: Isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐mononitrate (IS‐5‐MN) 80 mg single dose
Study: 31195354
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cetuximab (anti-EGFR-directed monoclonal antibody) in combination with capecitabine and cisplatin
Study: 31195354
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with capecitabine and cisplatin
Study: 29370022
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% ophthalmic solution
Study: 24456698
Drug: BMC+Phone (BMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC+Phone (BMC plus monthly phone calls by a Community Health Worker)
Study: 24456698
Drug: BMC+Home (BMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC+Home (BMC plus monthly home visits by a Community Health Worker)
Study: 21803976
Drug: NaClO(3) 60
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaClO(3) 60 mg·kg of BW(‐1)
Study: 21803976
Drug: NaClO(3) 90
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaClO(3) 90 mg·kg of BW(‐1)
Study: 21803976
Drug: NaClO(3) 150
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaClO(3) 150 mg·kg of BW(‐1)
Study: 21803976
Drug: NaClO(3) 300
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaClO(3) 300 mg·kg of BW(‐1)
Study: 21803976
Drug: NaClO(3) 450
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaClO(3) 450 mg·kg of BW(‐1)
Study: 21803976
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline NaCl, 30 mg·kg of BW(‐1) for lambs; 150 mg·kg of BW(‐1) for ewes)
Study: 19398935
Drug: (32)P‐chromic phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: (32)P‐chromic phosphate colloids (32)P‐CP) injection during surgery